Funding for this research was provided by:
Institute of Circulatory and Respiratory Health
Received: 21 August 2017
Accepted: 8 February 2018
First Online: 6 March 2018
: Additional author information is available at ExternalRef removed.
: All patients provided written informed consent. This protocol was reviewed and approved by the St. Paul’s Hospital/University of British Columbia research ethics board.
: Not applicable.
: JHB, JAR, and KRW report patents owned by the University of British Columbia (UBC) that are related to PCSK9 inhibitor(s) and sepsis. JHB, JAR, and KRW are founders and shareholders of Cyon Therapeutics, a company that holds patents for use of PCSK9 inhibitors to treat sepsis.JAR reports patents owned by the University of British Columbia (UBC) that are related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. JAR has share options in Leading Biosciences Inc. JAR is a shareholder in Molecular You Corp. JAR reports receiving consulting fees from:1. Cubist Pharmaceuticals (now owned by Merck; formerly was Trius Pharmaceuticals; developing antibiotics),2. Leading Biosciences (developing a sepsis therapeutic),3. Ferring Pharmaceuticals (manufactures vasopressin and is developing selepressin),4. Grifols (sells albumin),5. La Jolla Pharmaceuticals (developing angiotensin II; Dr. Russell chairs the Data Safety Monitoring Board (DSMB) of a trial of angiotensin II),6. CytoVale Inc. (developing a sepsis diagnostic),7. Asahi Kesai Pharmaceuticals of America (AKPA) (developing recombinant thrombomodulin).JAR reports having received an investigator-initiated grant from Grifols that is provided and administered by UBC.No other authors have any conflict of interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.